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Chronic sleep restriction in the 
rotenone Parkinson’s disease 
model in rats reveals peripheral 
early-phase biomarkers
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Parkinson’s disease (PD) is a chronic disorder that presents a range of premotor signs, such as sleep 
disturbances and cognitive decline, which are key non-motor features of the disease. Increasing 
evidence of a possible association between sleep disruption and the neurodegenerative process 
suggests that sleep impairment could produce a detectable metabolic signature on the disease. In 
order to integrate neurocognitive and metabolic parameters, we performed untargeted and targeted 
metabolic profiling of the rotenone PD model in a chronic sleep restriction (SR) (6 h/day for 21 days) 
condition. We found that SR combined with PD altered several behavioural (reversal of locomotor 
activity impairment; cognitive impairment; delay of rest-activity rhythm) and metabolic parameters 
(branched-chain amino acids, tryptophan pathway, phenylalanine, and lipoproteins, pointing to 
mitochondrial impairment). If combined, our results bring a plethora of parameters that represents 
reliable early-phase PD biomarkers which can easily be measured and could be translated to human 
studies.
Parkinson’s disease (PD) is a chronic neurodegenerative disease that typically affects dopaminergic neurons in 
the substantia nigra pars compacta (SNpc). However, other regions such as brainstem nuclei, cortical areas, spi-
nal cord, preganglionic sympathetic/parasympathetic neurons, as well as portions of the peripheral and enteric 
nervous systems are involved in the pathophysiology1–4. Before occurrence of the prominent motor signs, PD 
presents a range of non-motor symptoms (NMS) that precede the clinical motor phase by many years. Some are 
well-known, such as olfactory and gastrointestinal dysfunction, sleep disorders, circadian changes and cognitive 
impairment3,5–7. Moreover, neuropathological studies support the association of these early-phase disturbances 
based on the identification of Lewy bodies in non-dopaminergic nuclei in early Braak stages, prior to significant 
SNpc degeneration and motor signs2. Recent epidemiological studies propose that NMS can appear up to 25 years 
before the onset of clinical PD6, and it is well-established that patients report sleep disruption at least a decade 
before the first motor symptoms8. In animal models, the SNpc was shown to regulate sleep patterns9 and recently 
it was found that sleep-wake disturbance can predispose the brain to PD neuropathology10. Undoubtedly, sleep 
disorders represent an essential part of PD progression, once brain structures affected in the first stages of the 
disease11 and correspondent neurotransmitter systems are involved in sleep regulation12, but they are poorly 
investigated in the diagnosis.
Reduced total sleep time, sleep efficiency and sleep fragmentation, all leading to sleep loss, consistently emerge 
as sleep issues in PD13,14, but it is unclear if sleep loss constitutes a risk-factor for PD due to the lack of more spe-
cific prospective studies15. In general, these sleep alterations are one of the premotor features that most affect the 
patients’ quality of life, and could contribute to worsening cognitive abilities, such as memory impairment16,17, 
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apart from having a direct association with the motor impairment18. In this context, PD-related sleep disturbances5 
and society-imposed sleep restrictions19 may contribute to cognitive decline, and even emerge as an early bio-
marker of abnormal aging20, perhaps producing detectable changes in peripheral tissues in addition to behav-
ioural parameters, like memory deficits and circadian shifts. Despite much effort, there is as yet no reliable way to 
identify those individuals that will develop PD. Failure to establish the pathological process is the main obstacle 
to find a cure or treatment that alters the course of the disease, but our inability to diagnose it early enough hin-
ders a better approach or improvement of the existing treatments. Therefore, the identification of risk factors and 
detection of early symptoms are a priority, since no approach to date has identified specific or sensitive signs that 
have a practical application in diagnosis21,22. Metabolic phenotyping (metabonomics/metabolomics) using high 
resolution analytical chemistry platforms coupled with multivariate statistics provides great potential for iden-
tifying reliable biomarkers of PD. The elucidation of such biochemical signatures could represent a major step 
towards early diagnosis, disease progression, and effective treatments23,24.
Here we investigated, in the rotenone (ROT) animal model of PD, chronic sleep restriction (SR) as a possible 
triggering factor for peripheral metabolic changes, cognitive impairment and circadian alterations. Rotenone, a 
mitochondrial complex I activity inhibitor pesticide, mimics the hallmark traits of early-phase PD (equivalent to 
Braak stages 2–3) extending to NMS such as excessive daytime sleepiness, REM sleep behaviour disorder, insom-
nia and deterioration of spontaneous sleep, dopamine-dependent behavioural deficits, hyposmia and gastrointes-
tinal problems, as well as canonical pathological alterations, such as time-dependent reduction of dopaminergic 
nigrostriatal neurons, α-synuclein (PARK1) aggregation, Lewy-like body formation, oxidative stress and ultras-
tructural impairments in the SNpc mitochondria5,25–35. To identify the biochemical perturbations associated with 
SR in this model, two metabolic profiling platforms were applied to characterize the plasma metabolic signatures: 
global 1H nuclear magnetic resonance (NMR) spectroscopy and targeted liquid chromatography/mass spectrom-
etry (LC/MS).
Methods
Ethics Approval. All animal procedures were approved by the Ethics Committee of the Federal University of 
Paraná (approval ID #858) and conducted according to the guidelines of ethics and experimental care and use of 
laboratory animals (SBCAL). The research protocols were reviewed by The University of Surrey Animal Welfare 
Ethical Review Body (AWERB) and by the Named Veterinary Surgeon (NVS) prior to any work, in accordance 
with the principles of UK legislation (Animals [Scientific Procedures] Act 1986).
Experimental design. The experiments were performed on healthy male Wistar rats, 90 days old, weighing 
280–330 g, with normal immune status. Experimental animals were not involved in any previous test or drug 
treatment. The animals were group housed (4 per cage) in polypropylene cages with disposable bedding on a 
standard light-dark (L/D) cycle (12 h:12 h cycle, lights on at 07.00 h = ZT0) in a temperature controlled room 
(22 ± 2 °C). Food and water were provided ad libitum throughout the experiment.
Figure 1A shows the group distribution flowchart and a timeline diagram of the study design. The animals 
were randomly distributed in one of the groups: SHAM-CT (vehicle infusion and control for sleep restriction)/
SHAM-SR (vehicle infusion and sleep restriction condition)/SHAM-REB (vehicle infusion and sleep restriction 
condition followed by sleep recovery)/ROT-CT (rotenone infusion and control for sleep restriction)/ROT-SR 
(rotenone infusion and sleep restriction condition)/ROT-REB (rotenone infusion and sleep restriction condition 
followed by sleep recovery). Total of 6 groups, n = 24 animals per group, total number of 144 animals. The experi-
mental design was performed in 6 cohorts (6 groups with 4 animals each, total number of 24 animals per cohort).
One week before the experiments began, the animals were maintained in the room described above for habit-
uation. On day 0, the animals underwent stereotaxic surgery. After a 10 day interval for recovery, the animals 
were trained for the Object Recognition Task (ORT) and the following day the basal test (ORT 1) was performed 
prior to 21 days of sleep restriction (commencing on day 11). Every week, ORT was repeated on the same week-
day (ORT 2 = 7 days of SR; ORT 3 = 14 days of SR) until the end of sleep restriction (day 32 = 21 days of SR). On 
day 32, another ORT (ORT 4) was carried out, followed by an Open Field Test and then the control (CT) groups 
(SHAM-CT; ROT-CT) and half of the animals from the SR groups (SHAM-SR, n = 24, and ROT-SR, n = 24) 
were sacrificed. The other half of the SHAM-SR (n = 24) and ROT-SR (n = 24) groups were allowed sleep recov-
ery for 15 days (Rebound group (REB) – SHAM-REB and ROT-REB) at the end of the sleep restriction period. 
Throughout the experiment, animals’ activity was recorded daily for 21 days by infrared motion sensors after the 
6 h of sleep restriction and throughout the rebound period.
Stereotaxic surgery. The animals were initially sedated with intraperitoneal xylazine (10 mg/kg; Syntec do 
Brasil Ltda, Brazil) and anaesthetized with ketamine (90 mg/kg, i.p.; Syntec do Brasil Ltda, Brazil). For ROT (3 
groups, 24 animals per group, total number of 72 animals) or vehicle (dimethylsulfoxide - SHAM) (3 groups, 24 
animals per group, total number of 72 animals) infusion within the SNpc, the following coordinates was used, 
bregma as a reference: (AP) −5.0 mm, (ML) ± 2.1 mm and (DV) −8.0 mm36. Rotenone (12 µg/µl; Sigma-Aldrich®, 
St. Louis, MO, United States) or DMSO (Sigma-Aldrich®, St. Louis, MO, United States) infusions of 1 µL into each 
hemisphere were made at a rate of 0.33 µL/min for 3 min32,33,37. These infusions were made using an electronic 
infusion pump (Insight Instruments, Ribeirão Preto, SP, Brazil).
Sleep restriction procedure. SR (4 groups, 24 animals per group, total number of 96 animals) was per-
formed using a gentle handling/stimulation protocol, which consisted of soft tapping on the cage, gently shaking 
the cage or, when this was not sufficient to keep animals awake, gently disturbing the sleeping nest38. CT animals 
(2 groups, 24 animals per group, total number of 48 animals) were left undisturbed.
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Figure 1. Sleep restriction in the rotenone model of PD. (A) Group distribution and timeline diagram. 
Colours are representative of groups throughout the results. SR = Sleep Restriction; REB = Rebound sleep; 
SHAM = vehicle; ROT = rotenone; SHAM-CT = sham control for SR (blue); ROT-CT = rotenone control for 
SR (orange); SHAM-SR = vehicle SR (green); ROT-SR = rotenone SR (red); SHAM-REB = SHAM-SR after 15 
days of REB (yellow); ROT-REB = ROT-SR after 15 days of REB (purple); ORT = Object Recognition Task; 
OF = Open Field. (B) Representative immunohistochemistry labelling of TH-ir neurons at the end of SR for 
SHAM-CT, ROT-CT, SHAM-SR and ROT-SR. (C) Percentage of TH-ir expressing neurons in the SNpc in 
relation to the SHAM-CT group. Individual data are shown as a scatter plot with bar of mean ± standard error 
of the mean (SEM), n = 4 per group for CT (SHAM-CT and ROT-CT) and n = 5 per group for SR (SHAM-SR 
and ROT-SR). ****P ≤ 0.0001 sham compared to rotenone treated (two-way ANOVA followed by Fisher’s LSD 
test). (D) Locomotion parameter obtained from the open field test. Individual data (cm) are shown as a scatter 
plot with bar of mean ± SEM. *P < 0.05; **P ≤ 0.01 (two-way ANOVA followed by Fisher’s LSD test). n = 24 
SHAM-CT; n = 46 SHAM-SR; n = 20 ROT-CT; n = 41 ROT-SR. (E) Exploration index (ΔNF–F). Bars represent 
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Open Field (OF) Test. The OF test apparatus consisted of a circular arena (1 m diameter) limited by a 50 cm 
high wall. The animals were placed in the centre of the arena and allowed to freely explore the area for 5 min. The 
animals’ distance travelled was recorded by a digital camera coupled to the Smart Junior system (Panlab, Harvard 
Apparatus Spain, Barcelona, Spain)39.
Object Recognition Task. The ORT was performed in an open box (80 cm (W) × 80 cm (L) × 50 cm (H)) 
made of wood and covered with a black, opaque plastic film in dim light conditions. The objects to be discrimi-
nated were made of different materials, all of them previously covered with non-toxic varnish, so that the animals 
could not move them around in the arena. The objects are not known to have any ethological significance for the 
rats and had never been associated with reinforcement40. The first day of the experiment consisted of 4 familiari-
zation/training trials (3 min each, 15–20 min apart), in which two identical objects (familiar objects) were placed 
in the back corners of the open box, 10 cm away from the sidewall. The rat was placed in the open box facing away 
from the objects. Twenty-four hours after training, the first test of choice was performed (ORT 1), where one of 
the familiar objects was replaced by a new object (non-familiar for the animal). The test was repeated every seven 
days, when the non-familiar object was always replaced and the familiar one remained the same, totalling four 
tests for the animals that experienced daily sleep restriction only or control (ORT 2: 7 days after ORT 1; ORT 3: 
14 days after ORT 1; ORT 4: 21 days after ORT 1) and six ORT tests for the animals that remained in rebound 
after the end of the sleep restriction period (ORT 5: 28 days after ORT 1; ORT 6: 36 days after ORT 1). The time 
spent exploring each object was analysed by the same experimenter, blind to animal condition, to avoid operator 
bias. Exploration was defined as only occurring when the rat touched the object with its nose or the rat’s nose was 
directed towards an object at a distance ≤2 cm. The familiar/non-familiar object locations (left or right side of the 
arena) were counterbalanced within each experiment, as well as within-subject for subsequent experiments. The 
arena and objects were cleaned between each trial with 70% ethanol41. The results were calculated using the time 
spent by rats exploring the familiar (a′) and the non-familiar object (b) (Δ = b-a′)40.
Diurnal activity measurement. Overall activity of all animals in a cage was measured continuously after 
the sleep restriction and throughout the rebound period. Home cage activity was continuously recorded by pas-
sive infrared detectors connected to a computer that registered the motion (in-house apparatus). The device 
recorded the amount of activity in seconds in 5-minutes bins. Raw data were primarily analysed with the in-house 
software CTools 8.0.
TH-immunohistochemistry. For TH-immunoreactive (TH-ir) neurons quantification, the animals were 
anaesthetized with ketamine. Then, each animal was transcardially perfused with a saline solution, followed by 
a fixative solution of formaldehyde 4% in 0.1 M phosphate buffer (pH 7.4). After that, brains were removed from 
the skulls and were immersed in the fixative solution at 4 °C. Forty-eight hours later, the material was immersed 
in a 30% sucrose solution for three days and finally stored in a −80 °C freezer before sectioning. Nine 40 µm sec-
tions corresponding to SNpc (−4.92 mm and −5.28 mm/coordinates obtained from Paxinos and Watson36) were 
collected from 5 animals of each group. Three slices were randomly chosen from each animal and incubated with 
primary mouse anti-TH antibody (1:500; Chemicon, Rolling Meadows, IL, USA). Biotin-conjugated second-
ary antibody (1:200 anti-mouse; Vector Laboratories, Burlingame, CA, USA), was localized using the ABC sys-
tem (Vectastain ABC Elite kit, Vector Laboratories, Burlingame, CA, USA), followed by 3,30-diaminobenzidine 
reaction with nickel enhancement. Neuronal density determination was conducted using the software Image J 
(National Institutes of Health, Rockville, MD, USA). For each group, a mean value was calculated and converted 
to a percentage relative to the sham control group and compared with the other groups (data not shown for REB 
groups, which had no statistical differences to the correspondent SR group). The images were obtained using a 
motorized Axio Imager Z2 microscope (Carl Zeiss, Jena, Germany), equipped with an automated scanning VSlide 
(Metasystems, Altlussheim, Germany).
Sample collection for metabolomics. For metabolomics analyses, plasma samples were collected after 
decapitation. At this stage, brains were also removed from the skulls and structures of interest (SNpc, striatum 
and hippocampus) were dissected for later analysis. Following this, 10 mL of blood was placed into lithium hepa-
rin tubes, which were gently inverted 5–8 times. The samples were centrifuged immediately at 3200 rpm (1620 g) 
for 10 minutes at 4 °C and split into aliquots (1 mL and 25 µl). The plasma aliquots were placed immediately into 
a −80 °C freezer. The samples were stored at −80 °C prior to being shipped on dry ice to the UK (University of 
Surrey/Imperial College) for LC/MS or NMR metabolomics analysis.
Targeted metabolomics analysis (LC/MS). Plasma samples were measured using the AbsoluteIDQ® 
p180 targeted metabolomics kit (Biocrates Life Sciences AG, Innsbruck, Austria), and a Waters Xevo TQ-S mass 
spectrometer coupled to an Acquity UPLC system (Waters Corporation, Milford, MA, USA) similar to our pre-
vious studies42–44. Plasma samples (10 μl) were prepared according to the manufacturer’s instructions adding 
several stable isotope–labelled standards to the samples prior to the derivatization and extraction steps. Using 
the mean (±SEM) time exploring objects (s). *P < 0.05 (two-way ANOVA followed by Fisher’s LSD test). ORT 
1 = First test, before SR; ORT 2 = second test (SR = 7 days); ORT 3 = third test (SR = 14 days); ORT 4 = fourth 
test (SR = 21 days). n = 24 SHAM-CT; n = 24 SHAM-SR; n = 20 ROT-CT; n = 20 ROT-SR. NF = non-familiar 
object; F = familiar object. (F) Learning curve comparing SHAM-CT and ROT-SR during the SR protocol. Time 
exploring objects (ΔNF–F) values (s) are expressed as mean ± SEM. *P < 0.05; **P ≤ 0.01 (one-way repeated-
measures ANOVA followed by Fisher’s LSD test). n = 24 SHAM-CT; n = 20 ROT-SR.
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either LC/MS or flow injection analysis/MS up to 183 metabolites from 5 different compound classes (namely 
acylcarnitines, amino acids, biogenic amines, glycerophospholipids and sphingolipids) can be quantified. All 
the plasma samples and 3 levels of quality control (QC) were processed on a single 96-well plate, sample order 
being randomised. The levels of metabolites present in each QC were compared to the expected values and the 
percent coefficient of variation (CV%) calculated. Metabolites where >25% concentrations were below the limit 
of detection (<LOD) or below lower limit of quantification (≪LLOQ) or above limit of quantification (>LOQ) or 
blank out of range, or the QC2 coefficient of variance was >30%, were excluded (n = 50)43,44. The remaining 133 
quantified metabolites comprised 10 acylcarnitines, 21 amino acids, 12 biogenic amines, 76 glycerophospholipids 
and 14 sphingolipids.
¹H NMR spectroscopy. Plasma samples were prepared as described by Beckonert, et al.45. 1H NMR spec-
troscopy was performed at 310 K on a Bruker 600 MHz spectrometer (Bruker Biospin, Karlsruhe, Germany). For 
each sample, water-suppressed Carr-Purcell-Meiboom-Gill spin-echo spectra were recorded. In this experiment, 
eight dummy transients were followed by 64 transients and collected in 64 K data points. NMR spectra were man-
ually corrected for phase and baseline distortions and referenced to the anomeric proton of β-glucose at δ 5.223.
Quantification and Statistical Analysis. Animals were randomly assigned to experimental groups, with 
no specific randomization strategy. The criteria for calculating the sample size was established from the for-
mula that establishes the sample size for a finite population: n = [N. σ². (Zα/2)²]/[(N-1).E² + σ². (Zα/2)²], where 
n = number of individuals; Zα/2 = critical value that corresponds to the desired confidence interval; E = the max-
imum error of the estimate; N = population size; σ = population standard deviation. Thus, the following equation 
was used for this study: N = 10. 52. (1.96) 2/(10-1) 0.052 + 52. (1.96) 2 = 9.99 ≅ 10 (sample number per group/
parameter). Consequently, it was stipulated that each group should comprise a sample number of 10 rats for each 
analysis.
For behavioural data, statistical analysis was performed using GraphPad Prism Version 6.0 (GraphPad 
Software, La Jolla, CA, USA) and Statistica Version 12 (StatSoft Inc, Tulsa, OK, USA). Values were presented as 
mean ± SEM. Homogeneity of variance was assessed by the Bartlett test and normal distribution of the data was 
assessed by the Kolmogorov-Smirnov test. Statistical significance for behavioural results was set at P < 0.05. Data 
inclusion was determined by The ROUT method of identifying outliers (Q = 10%) for the Open Field Test and by 
the Box Plot Diagram to identify outliers for the Object Recognition Task, where an outlier was that with a value 
more than 1.5 times the interquartile range above the third quartile or below the first quartile (animals with 3 or 
more values excluded from the ORT tests, outlier or data acquisition issues, had all values excluded).
Statistical analysis of TH-immunohistochemistry, Open Field Test, Object Recognition Test and Rest-activity 
pattern was performed using two-way ANOVA followed by Fisher’s LSD test, using treatment (SHAM/ROT) and 
procedure (CT/SR/REB) as independent variables. For the learning curve of Object Recognition Test, a one-way 
repeated-measures ANOVA followed by Fisher’s LSD test was performed using the Δ (Δ = b-a′) of each group.
LC/MS metabolomics analysis: multivariate analysis was performed by principal component analysis (PCA) 
and orthogonalized partial least squares discriminant analysis (OPLS-DA), using SIMCA-P v13.0 software 
(Umetrics, Umeå, Sweden) and default software settings. Whereas PCA looks at overall variation (unsupervised), 
OPLS-DA distinguishes between class-predictive (discriminating) variation (supervised) and non-predictive 
(orthogonal) variation. The use of these methods allows insight into the extent and underlying patterns of 
class-predictive variation within the data set as a whole. Differences in individual metabolite levels were ana-
lysed in R version 3.1.2 (R Foundation for Statistical Computing, Vienna, Austria) using the linear models and 
ANOVA methods in the stats package. Linear models were fitted to the treatment (SHAM/ROT) and procedure 
(CT/SR/REB). Significant differences for all parameters and their interaction were determined using multivar-
iate ANOVA. P-values were corrected for multiple comparisons according to the Benjamini-Hochberg False 
Discovery Rate (FDR). Metabolites were considered as significant at an FDR cutoff < 0.05. For testing statis-
tical significance, missing values (n = 15) were not taken into account. For data visualisation, we used a heat 
map combined with hierarchical clustering (Euclidean distance and Ward linkage). Prediction models based on 
combinations of metabolites were made by logistic modelling in R statistical software. First, metabolites were 
selected that met the following criteria: a significant (FDR < 0.05) difference between the control and group of 
interest in the ANOVA model; a (non-cross-validated) Area Under the Curve (AUC) that was significantly higher 
than for randomly permutated values (P < 0.05, determined by 10,000 permutations); and a difference in plasma 
concentration of more than 5% between groups. For the markers that met these criteria, logistic models were 
made using log-transformed values. The predictive performance of the models was tested by determining the 
AUC using leave-one-out cross-validation, in which a model was trained using data of all-but-one and tested on 
the remaining rat. Using this approach, models were developed by stepwise testing the result of adding another 
metabolite to the current model and selecting the metabolite with the highest gain in AUC to be included in 
the model for the next step. This was repeated until no further improvement in AUC could be achieved. For the 
models obtained, predictions were shown by Receiver Operating Characteristic (ROC) visualisation. Finally, for 
determining sensitivity and specificity of the SR models, samples with a predicted probability of more than 50% 
were considered predicted as SR, whereas samples with a predicted probability of less than 50% were considered 
predicted as not-SR.
NMR spectroscopy: Spectra were digitized using an in-house MATLAB (version R2009b, The Mathworks, 
Inc.; Natick, MA, USA) script. The spectral region containing the water resonance was excised from the spectra. 
PCA was then performed with Pareto scaling in Matlab46. Overview PCA analysis identified 4 outliers in the data 
set (1 due to high plasma lactate; 3 had high plasma glucose). These samples were removed from subsequent 
analyses, including OPLS-DA analysis performed using in-house scripts in Matlab.
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Results
Rotenone lesion combined with Sleep Restriction altered locomotor activity, lead to cognitive 
impairment and delay of rest-activity rhythm. Characterization of dopaminergic neuronal loss 
by TH immunohistochemistry in the SNpc (representative photomicrographs Fig. 1B) showed that Rotenone 
(ROT) (12 µg/µl) infusion (1 µl at 0.33 µl/min) induced a decrease of TH-ir neurons when compared to the sham 
groups (SHAM-CT vs. ROT-CT = 49% reduction; SHAM-CT vs. ROT-SR = 61% reduction; SHAM-SR vs. 
ROT-CT = 57% reduction; SHAM-SR vs. ROT-SR = 69% reduction), [F(1,14) = 74.58; P < 0.0001] (Fig. 1C). SR 
did not have a significant effect overall. The percentage reduction of TH-ir neurons was maintained after 15 days 
of sleep recovery (REB) (Fig. S1A).
In order to evaluate the integrity of the locomotor activity we analysed the animals’ performance on Open 
Field Test. As can be seen in Fig. 1D, the ROT-CT group, on day 32, exhibited a decrease in the distance travelled 
in the OF compared with all other groups on the same day, with an effect both of the lesion [F (1,125) = 4.415; 
P < 0.05] and of the sleep restriction [F(1,125) = 3.964; P < 0.05]. After REB, there was no statistical difference 
between the groups (Fig. S1B).
We used the Object Recognition Test – a measure where the time spent on a new object presented to the ani-
mal permits to evaluate recognition memory – to estimate the cognition status. The sham CT group exhibited 
a significant learning curve as shown by the memory improvement over subsequent tasks [F (83.544) = 3.129; 
P < 0.05], with a marked difference between ORT1/2 and ORT4 (P < 0.05) (Fig. 1E). In each test, a two-way 
ANOVA followed by Fisher’s LSD test between groups was performed revealing that in the last test (ORT4) 
SR impaired both SHAM (P < 0.05) and ROT (P < 0.01) groups compared to SHAM-CT (Fig. 1F), which was 
Figure 2. Rest-activity parameters. (A) Daily activity pattern of each group (seconds/5 minutes) during 
the sleep restriction (SR) period. Each line represents the mean activity (±SEM) across the 21 days of SR. 
ZT0 = lights on and the beginning of gentle handling until ZT6 when recording started. n = 6 per group for 
CT (SHAM-CT and ROT-CT) and n = 12 per group for SR (SHAM-SR and ROT-SR). (B) Activity profile 
15 minutes before and 2 hours after the onset of darkness (ZT12) during weeks 2 and 3 after the start of SR. 
Each line represents the mean activity (seconds/5 minutes) of the 14 days (±SEM). Ticks on x axis represent 
5-minutes blocks. *P < 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001 (two-way ANOVA followed by Fisher’s 
LSD test). Orange (*) = ROT-CT compared to ROT-SR; Blue (*) = ROT-SR compared to SHAM-SR; Green 
(*) = ROT-SR compared to SHAM-SR. n = 6 per group for CT (SHAM-CT and ROT-CT) and n = 12 per group 
for SR (SHAM-SR and ROT-SR). (C) Daily activity pattern each week of the 3 weeks of SR. Each line represents 
the mean activity (seconds/5 minutes) of 7 days ± SEM. ZT0 - lights on and the beginning of gentle handling 
until ZT6 when recording started. n = 6 per group for CT (SHAM-CT and ROT-CT) and n = 12 per group for 
SR (SHAM-SR and ROT-SR). (D) Total activity/day (h) in each of the 3 weeks of SR. The bars represent the 
mean ± SEM. *P < 0.05; **P ≤ 0.01; ***P ≤ 0.001 (two-way ANOVA followed by Fisher’s LSD test). n = 24 
SHAM-CT; n = 24 SHAM-SR; n = 20 ROT-CT; n = 20 ROT-SR.
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the only group that explored the non-familiar object significantly more after ORT2 (Fig. S2). Moreover, in the 
first week of sleep rebound, significant memory impairment in the ROT-REB group compared to SHAM-REB 
(P < 0.05) was observed. However, after 15 days of sleep rebound, this difference between the groups disappeared 
(Fig. S1C).
The assessment of the activity pattern to observe possible rest-activity alterations was performed using an 
infrared beam-break system. The two-way ANOVA analysis revealed that there was a statistical difference in the 
diurnal activity profile among groups [F (3,6912) = 38.56; P < 0.0001] at several time-points [F (215,6912) = 87.72; 
P < 0.0001] over the 21 days of SR (Fig. 2A). There was a consistent diminished activity level in the ROT-SR group 
starting at ZT12 (lights-off; 19:00 h clock time) that remained lower for at least 1 hour after the onset of darkness. 
This difference was not seen in the first week but emerged and became statistically significant in weeks 2 and 3 
(Fig. 2C). We investigated the first 2 hours of the dark phase in the course of weeks 2 and 3 in more detail, and this 
analysis showed that the ROT-SR group exhibited significantly reduced activity [F (3,100) = 220.4; P < 0.0001] 
during the 75 minutes after lights-off, suggesting reduced behavioural arousal (Fig. 2B). Total activity also showed 
a progressive decline each week in the SR groups: in week 1 [F (1,83) = 4.753; P < 0.05] only ROT-SR showed a 
significant difference from SHAM-CT (P < 0.05); in the second week both SR groups showed reduced activity [F 
(1,83) = 12.94; P < 0.001] that was even more evident in week 3 [F (1,83) = 19.46; P < 0.0001] (Fig. 2D). On the 
first day after SR ended, both SHAM and ROT groups exhibited a disturbed rest-activity rhythm throughout the 
day, which recovered over time (Fig. S3).
Plasma metabolic profiling. Targeted LC/MS-based metabolic profiling was used to examine the effect of 
phenotype (ROT vs SHAM) and sleep condition (CT vs SR) on plasma metabolite concentrations. A pair-wise 
orthogonal partial least-squares discriminant analysis (OPLS-DA) model was obtained comparing the plasma 
metabolic profiles of SHAM-CT animals with ROT-CT animals (Fig. 3A); R²X = 0.636; R²Y = 0.996; Q²Y = 0.312; 
n = 1 + 5 components. This model was not significant (CV ANOVA P > 0.05). The corresponding p(corr) loading 
plot is shown in Fig. 3B and the p(corr) values for each metabolite are presented in Supplementary Table S1A. 
ROT treatment was associated with increased plasma branched-chain amino acids (BCAA) (leucine (LEU), 
isoleucine (ILE), valine (VAL)), ornithine and 33 phospholipids (p(corr) > 0.3) and decreased circulating 
alpha-aminoadipic acid (α-AAA) and propionylcarnitine (AC-C3) (p(corr) < −0.3) (Fig. 3B; Table S1A). By 
contrast a significant difference was observed in the SHAM-SR group compared to SHAM-CT. A significant 
pair-wise OPLS-DA model comparing SHAM-CT with SHAM-SR (R²X = 0.421; R²Y = 0.934; Q²Y = 0.525; 
n = 1 + 2 components; CV ANOVA P = 0.04; validated by permutation analysis) is shown in Fig. 3C, the p(corr) 
loading plot is shown in Fig. 3D and the p(corr) values for each metabolite are presented in Supplementary 
Table S1B. Sleep restriction in control animals increased plasma concentrations of the BCAAs (LEU, ILE, VAL), 
ornithine, arginine, lysine, alanine, proline, phenylalanine (PHE), carnitine (AC-C0), and phospholipids (n = 15) 
(p(corr) > 0.3) and decreased creatinine, putrescine, symmetric dimethylarginine, kynurenine (KYN), α-AAA, 
trans-4-hydroxyproline, acetylcarnitine (AC-C2), tetradecenoylcarnitine (AC-C14:1) and glutaconylcarnitine 
(AC-C5:1-DC) (p(corr) < −0.3) compared to controls. A significant pair-wise comparison OPLS-DA model was 
also obtained comparing SHAM-CT with ROT-SR (R²X = 0.499; R²Y = 0.920; Q²Y = 0.566; n = 1 + 2 compo-
nents; CV ANOVA P = 0.03; validated by permutation analysis; Fig. 3E). The p(corr) loading plot is shown in 
Fig. 3F and the p(corr) values of the metabolites are presented in Supplementary Table S1C. Sleep restriction 
with ROT increased plasma concentrations of the BCAAs (LEU, ILE, VAL), ornithine, arginine, lysine, proline, 
PHE, serine, spermidine, the sphingolipid (SM C16:1) and many phospholipids (n = 54) (p(corr) > 0.3) and 
decreased creatinine, trans-4-hydroxyproline, acetylcarnitine (AC-C2) and tetradecenoylcarnitine (AC-C14:1) 
(p(corr) < −0.3) compared to controls (SHAM-CT). After rebound, the effects of SR and ROT were lost 
(SHAM-CT vs ROT-REB) (OPLS-DA model R2X = 0.350, R2Y = 0.348, Q2Y = 0.216; n = 1 + 0 components; CV 
ANOVA P = 0.113).
ANOVA analysis was performed to assess differences in metabolite concentration ratios. Before this analysis, 
a heat map combined with hierarchical clustering was performed (Fig. S4A). Statistical analysis with one-way 
ANOVA (simple six-group - SHAM/ROT - CT, SR and rebound group- comparison, straightforward approach) 
identified 10 metabolites that were significantly different between the study groups when compared to SHAM-CT 
(FDR < 0.05): ILE, LEU, VAL, alpha-AAA, KYN, PC aa C30:0, PC aa C34:1, PC aa C40:2, PC aa C42:4, and PC 
ae C38:3 (shown in Table 1 with FDR values). Multivariate ANOVA including all groups showed 3 significant 
metabolites (ILE, LEU – increased; KYN – decreased) due to SR if compared to SHAM-CT and no differences 
for the rotenone lesion. Table 1 shows the metabolite ratios compared to control (SHAM-CT) and FDR values 
per comparison. Models including interactions did not present any metabolites with FDR < 0.10. Results after 
rebound show different metabolites altered, either if compared to SR or CT. Supplementary Fig. S4B shows the 
hits from one-way and multivariate ANOVA combined for all groups, including rebound. Using logistic pre-
diction modeling, models were built to predict whether samples were exposed to ROT, SR or rebound. Starting 
from no model, models were developed by adding one metabolite at a time to an existing model until no further 
improvement in AUC was obtained. For ROT, since no metabolites were significant, the best model was only with 
PC aa C40:2 (FDR = 0.072; AUC = 0.669), adding other metabolites did not improve AUC. For SR, the simplest 
model was based on KYN and stepwise improvement combined with leave-one-out cross-validation resulted in 
a final model with KYN and ILE (AUC = 0.845) (Fig. 4A). This model allowed 80% accuracy, 70% sensitivity and 
86% specificity. ROT animals were more often correctly predicted as SR (ROT-SR n = 11; n = 9 predicted as SR) 
than SHAM (SHAM-SR n = 12; n = 7 predicted as SR).
We also performed a correlations analysis (Fig. 5) to see if any of the parameters could be associated, con-
sidering only the correlation with an r > 0.4 or < −0.4, since this value is approximately the threshold where 
the tested correlations become significant with FDR < 0.05. For illustration purposes, we show the correlation 
between sleep condition and total activity on day killed, with r = −0.57. For metabolite concentrations, there was 
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a correlation between SR and KYN (r = −0.51), ILE (r = 0.41) and LEU (r = 0.42). Considering the behavioural 
and metabolomics data, a correlation between total activity on day killed and methionine (MET) concentra-
tions was demonstrated (r = 0.41). All the other correlations found were between metabolite concentrations, all 
increased in the model: LEU × ILE (r = 0.90); PHE × ILE (r = 0.50); VAL × ILE (r = 0.94); PHE × LEU (r = 0.52); 
VAL × LEU (r = 0.89); PHE × MET (r = 0.73); tryptophan (TRP) × MET (r = 0.64); MET × VAL (r = 0.41); 
PHE × VAL (r = 0.55); PHE × TRP (r = 0.58).
¹H NMR spectroscopy was used for untargeted metabolic profiling of the plasma samples. A significant 
OPLS-DA model was obtained comparing the plasma metabolic profiles between SHAM-CT and ROT-CT 
groups (R2X = 0.56, R2Y = 0.75, Q²Y = 0.35; P = 0.027 following 999 permutations). The corresponding coeffi-
cient plot is shown in Fig. 6A. Plasma from the ROT-CT group contained lower amounts of dimethylsulfone 
and pyruvate compared to the SHAM-CT group, but the most evident differences were associated with higher 
Figure 3. OPLS-DA plots in LC/MS targeted metabolomics data. (A) OPLS-DA scores plot showing 
separation by phenotype between the sham control group (SHAM-CT, dark blue, n = 11) and the rotenone 
control (ROT-CT, orange, n = 10); R2X 0.636; R2Y 0.996; Q²Y 0.312; P < 0.05. (B) OPLS-DA loading plot of 
SHAM-CT vs ROT-CT. Negative p(corr) values represent decreased and positive p(corr) values represent 
increased metabolite concentrations in the rotenone group (ROT-CT) compared to sham group (SHAM-CT). 
The metabolite bars are colour coded according to metabolite class as follows: amino acids and biogenic amines 
(blue); acylcarnitines (green); lysophosphatidylcholine acyl (lyso PC a) (dark orange); phosphatidylcholine 
diacyl (PC aa) (yellow); phosphatidylcholine acyl-alkyl (PC ae) (light orange); sphingolipids (SM) (brown). (C) 
OPLS-DA scores plot showing separation by sleep restriction alone (blue, SHAM-CT, n = 11; green, SHAM-SR, 
n = 12); R2X 0.421; R2Y 0.934; Q²Y 0.525; P = 0.04. (D) OPLS-DA loading plot of SHAM-CT vs SHAM-SR. 
Negative p(corr) values represent decreased and positive p(corr) values represent increased metabolite 
concentrations in sleep restriction (SR) compared to control. (E) OPLS-DA scores plot for SHAM-CT vs 
ROT-SR (dark blue, SHAM-CT, n = 11; dark red, ROT-SR, n = 11); R²X 0.499; R²Y 0.920; Q²Y 0.566; P = 0.03. 
(F) OPLS-DA loading plot of SHAM-CT vs ROT-SR. Negative p(corr) values represent decreased and positive 
p(corr) values represent increased metabolite concentrations in rotenone and SR compared to sham control.
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circulating amounts of triglycerides and lipoproteins (specifically, low density lipoproteins (LDL) and very-low 
density lipoproteins (VLDL) in the ROT-CT group). Consistent with the targeted LC/MS metabolomics, there 
was an increase in all BCAAs in the ROT-CT compared to the SHAM-CT group. However, a comparison between 
the sham groups (SHAM-CT vs SHAM-SR) did not reveal any significant difference produced by sleep restriction 
itself, in contrast to LC/MS analysis. Nevertheless, when comparing the additive effects of ROT and SR (ROT-SR) 
with SHAM-CT, the predictive ability of the OPLS-DA model was stronger (R2X = 0.59, R2Y = 0.91, Q2Y = 0.70, 
P = 0.001 following 999 permutations; Fig. 6B) than ROT alone (SHAM-CT vs ROT-CT; Q2Y = 0.35). While the 
increase in lipoproteins observed in the ROT-CT group remained, the increase in BCAAs was more pronounced 
with additional increases in TRP, PHE and glycerophosphocholine (GPC). After rebound, the additive effects pro-
duced by SR in ROT were lost (SHAM-CT vs ROT-REB) (OPLS-DA model R2X = 0.27, R2Y = 0.40, Q2Y = 0.19; 
P = 0.068).
Ratios to CT SHAM CT SHAM SR ROT CT ROT SR
FDR
one-way 
ANOVA
Multivariate ANOVA
SR Rotenone
Isoleucine 1.00 1.22 1.12 1.35 0.021 0.039 0.300
Leucine 1.00 1.26 1.18 1.40 0.021 0.039 0.261
Valine 1.00 1.21 1.12 1.33 0.014 0.061 0.285
Alpha-AAA 1.00 0.87 0.72 0.92 0.032 0.432 0.862
Kynurenine 1.00 0.79 1.15 0.72 0.028 0.014 0.799
PCaaC30:0 1.00 1.19 1.17 1.36 0.021 0.622 0.275
PCaaC34:1 1.00 1.21 1.17 1.43 0.049 0.529 0.275
PCaaC40:2 1.00 1.02 1.13 1.48 0.028 0.771 0.072
PCaaC42:4 1.00 1.01 1.00 1.26 0.028 0.871 0.489
PCaaC38:3 1.00 1.10 1.27 1.49 0.034 0.357 0.128
Table 1. Metabolite concentration ratios compared to control (SHAM-CT) and FDR values per comparison. 
Statistical analysis with one-way ANOVA showed 10 metabolites with significant differences (FDR < 0.05) 
listed here. Multivariate ANOVA showed 3 metabolites significantly altered (highlighted in bold) due to SR in 
comparison to SHAM-CT and no differences for rotenone lesion.
Figure 4. Receiver operating characteristic (ROC) plots of SR prediction models. Models were improved 
stepwise by including an additional metabolite until no more gain in AUC could be obtained during cross-
validation. Model 1: kynurenine (KYN) (black); AUC = 0.777. Model 2: kynurenine and isoleucine (ILE) (red); 
AUC = 0.845.
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Discussion
Using the established ROT rodent model of PD, we have shown that chronic SR can affect the behavioural and 
metabolic characteristics in this model consistent with PD. Collectively, these data reinforce the concept that SR 
in PD contributes to the development of metabolic shifts early in the disease (equivalent to Braak stages 2–3) 
that could aggravate its progression and be established as reliable early-phase predictive biomarkers. In addition, 
our work contributes to the consolidation of the ROT-PD model as a reliable model to study PD features. The 
ROT-PD has established itself more and more as a prototypical model to study sleep aspects related to the SNpc 
dopaminergic lesion. Previous studies have shown that both chronic systemic administration and stereotaxic 
injection of ROT were associated with sleep alterations, as long-term and progressive deterioration of spontane-
ous sleep35 and decrease of the time in NREM sleep33.
In the ROT-treated compared to the SHAM animals a selective reduction in the percentage of TH-ir neu-
rons within the SNpc, which is related to several NMS that are landmarks of early-phase features of PD, was 
observed9,32,33,37. Dopamine depletion within the SNpc leads to an increase in striatal D2 receptors, increasing 
activity of the nigrostriatal indirect-pathway resulting in movement impairment47. In addition, a dopaminergic 
lesion selectively decreases the synaptic strength of thalamic inputs into the direct-pathway, suggesting that motor 
impairments occur as a result of an imbalanced activation of basal ganglia circuitry by the thalamus, which can be 
reversed with thalamic inhibition48. The reduction in motor activity seen in the ROT-CT group, also observed in 
other ROT-PD models39,49, was reversed in the ROT-SR group, indicating that SR triggers a dopaminergic com-
pensatory mechanism. This is in agreement with Ramanathan, et al.50, who showed that a 6 h SR protocol of gentle 
handling produced an increase in exploratory behaviour. Similarly, 24 h of total sleep deprivation produced the 
same outcome, without changes in plasma corticosterone, suggesting that the increase in locomotor activity was 
not a consequence of the hypothalamic-pituitary-adrenal stress response51. REM sleep deprivation is also able to 
augment locomotion39 and counterbalance PD model-induced hypokinesia52, a compensatory effect considered 
to be due to supersensitivity of brain dopamine receptors53, specifically, through D2 receptor up-regulation54. 
Therefore, total SR can lead to a substantial loss of REM sleep, enough to compensate for the motor impairment 
produced by ROT lesion.
Substantial evidence supports the idea that sleep deprivation or SR impairs memory processes55–59 as a result 
of different mechanisms: (i) reduction of thalamic activity60; (ii) decline of hippocampal long-term potentiation61; 
(iii) decrease of hippocampal AMPA receptor function62; (iv) brain inflammation and increasing susceptibility 
to toxins63. Therefore, our ORT findings, showing that the ROT-SR group was not able to remember the familiar 
object, are aligned with the results of Dos Santos, et al.39, showing that ROT can impair object recognition, but, 
Figure 5. Behavioural and neurochemical correlations. Correlations with an r > 0.4 or <−0.4 were considered 
since this value is approximately the threshold where the tested correlations become significant with 
FDR < 0.05. From the top left to the bottom right: total activity on day killed × Sleep Condition (r = −0.57); 
LEU × Sleep Condition (r = 0.42); total activity on day killed × MET (r = 0.41); MET × VAL (r = 0.41); 
KYN × Sleep Condition (r = −0.51); PHE × ILE (r = 0.50); PHE × LEU (r = 0.52); PHE × VAL (r = 0.55); 
ILE × Sleep Condition (r = 0.41); PHE × MET (r = 0.73); TRP × MET (r = 0.64); PHE × TRP (r = 0.58). Colour 
code: dark blue, SHAM-CT, n = 11; green, SHAM-SR, n = 12; orange, ROT-CT, n = 10; dark red, ROT-SR, 
n = 11.
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unlikely the acute REM sleep deprivation which improved memory, our chronic protocol suggest a significant 
synergistic effect of SR and the dopaminergic ROT lesion in the maintenance of cognitive impairment. It is note-
worthy that ORT is a familiarity-based memory task, which is correlated to human episodic-like memory and 
spatial learning, both impaired in early-stage PD, suggesting that the basal ganglia interact with the prefrontal 
cortex to mediate high-level cognition64,65. Basal ganglia influence cortical learning-dependent synaptic plasticity 
by selectively modulating corticostriatal inputs; in a dopamine depletion background, this plasticity is altered due 
to unsuitable filtering by the basal ganglia, resulting in abnormal learning66. It is known that significant areas for 
object recognition in rats are cortical association areas, the mediodorsal thalamic nucleus, the rhinal cortices, 
especially the perirhinal, and the prefrontal cortical areas67,68. These structures have primary projections to the 
striatum and there is evidence that the striatum modulates information flow to the prefrontal cortex69, providing 
the background for cognitive impairment.
There is also evidence for effects of circadian disruption in long-term object recognition, independent of 
sleep70. The observed rest-activity patterns revealed that the ROT-SR group showed significantly reduced arousal 
during the first hour of night-time activity (their active phase), suggesting attenuated behavioural arousal and an 
association between sleep and circadian changes in a PD context. Circadian disruption in PD could reflect not 
only sleep disturbances but also autonomic, cognitive, psychiatric and motor impairments, further endorsed by 
the role that dopamine has in sleep regulation and circadian homeostasis5,7,71. Lastly, it is plausible that the mech-
anisms that affect the circadian system in PD could influence sleep/wake processing. Therefore, the occurrence of 
one reinforces the progression of the other, potentially involving a feedback mechanism72, predisposing the brain 
to neurodegeneration through a number of key mechanisms73.
To elucidate the biochemical processes through which chronic SR can enhance the PD phenotype in the ROT 
model, we combined behavioural testing with targeted LC/MS and untargeted NMR spectroscopy based meta-
bolic profiling. Targeted metabolomics quantifies a large number of known metabolites, enabling the detailed 
characterization of changes in specific metabolic pathways in response to stimuli (ROT and/or SR)44. Untargeted 
1H NMR spectroscopy-based metabolic profiling is complementary to the targeted approach, measuring an 
extensive range of metabolites, both endogenous and exogenous, providing a holistic overview of the metabolic 
system and how it is modulated by different exposures46. This dual approach provides wide metabolome coverage 
Figure 6. OPLS-DA models comparing the plasma ¹H NMR spectral profiles. (A) OPLS-DA from SHAM-CT 
versus ROT-CT (Q2Y = 0.35, P = 0.027). LDL = Low density lipoproteins; VLDL = very low density lipoproteins 
(dark blue, SHAM-CT, n = 10; orange, ROT-CT, n = 9; dark red, ROT-SR, n = 6). (B) OPLS-DA from 
SHAM-CT versus ROT-SR (Q2Y = 0.70, P = 0.001).
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and, in this study, significant metabolic alterations were observed in the animals, mainly due to SR associated with 
the ROT-induced dopaminergic lesion.
ROT treatment was observed to increase the plasma lipoproteins, LDL and VLDL. This occurred both in the 
presence and absence of SR. VLDL is responsible for transporting energy-rich triacylglycerol to cells in the body 
while LDL is responsible for delivering cholesterol. Hypercholesterolemia has become a prognostic risk factor 
for neurodegenerative diseases, even contributing to PD onset74. Indeed, elevated cholesterol is associated with 
the loss of dopaminergic neurons in the SNpc, followed by a reduction in striatal dopamine levels, as a product 
of mitochondrial dysfunction, that leads to motor impairment75. Lipoprotein lipase (LPL) is the enzyme that 
removes triacylglycerol from VLDL transforming it into LDL. LPL is highly expressed in hippocampal neurons. 
Additionally, LPL is involved in the pathogenesis of dementia76–78 and LPL-deficient mice have been shown to 
have presynaptic dysfunction and impaired memory function79. Interestingly, ROT lesion was already linked 
to lipid impairment, with alterations in polyunsaturated fatty acid cardiolipin in the SNpc and plasma in rats80.
A family of metabolites suggested to be involved in lipid metabolism, implicated in insulin resistance and 
obesity, are the BCAAs81, which were found to be significantly elevated in our model. In SR rats compared to 
non-SR controls, LEU, ILE and KYN were significantly altered, with a statistical correlation for the sleep condi-
tion. Although LEU and ILE were increased in all groups in comparison with SHAM-CT, the most prominent 
increment was in the ROT-SR group. The remaining BCAA, VAL, showed a non-significant trend (P = 0.061) 
to increase (measured by targeted metabolomics), which was corroborated by the untargeted approach with all 
BCAAs showing increased plasma levels in the ROT-SR condition (there was also a slight increase in ROT-CT 
only, but SR appears to enhance this effect). These findings are in accordance with previous studies that have 
shown increased BCAA levels in PD patients, notably ILE and LEU82,83, and in PD animal models84. The patho-
physiological significance of these changes is still unclear, but it is known that impaired BCAA metabolism results 
in greater circulation of these BCAAs, and consequent mitochondrial dysfunction85. They are also transported 
into the brain via the large neutral amino acid transporter, which also transports TRP, PHE and tyrosine (TYR). 
Increased plasma BCAA levels reduce TRP and TYR transport into the brain due to competition for the carrier at 
the blood-brain barrier, influencing synthesis and release of serotonin and catecholamines (most notably dopa-
mine, by reducing tyrosine available for hydroxylation) within the brain86. TRP is the precursor of serotonin, 
which is involved in sleep/wake regulation, functioning primarily to promote wakefulness and closely related to 
memory and emotional processes in PD37,87. Competition between BCAA and TRP/TYR for brain uptake could, 
therefore, negatively impact serotonin and dopamine metabolism, contributing to the occurrence of NMS in PD.
Interestingly, TRP was also found to be higher in the plasma of the ROT-SR group compared to the SHAM-CT 
group (measured by NMR). TRP metabolism was found to be altered in early-stage PD patients in the study of 
Luan, et al.82, with TRP catabolites increased in the urine compared to healthy subjects, particularly KYN. There 
are some studies showing the involvement of KYN metabolism in PD88–90, and in our plasma samples, KYN 
was found to be decreased as a result of SR but not ROT. The KYN pathway, after its conversion from TRP by 
indoleamine 2,3-dioxygenase, produces three metabolites that have important roles in the brain: two of them, 
quinolinic acid and 3-hydroxyl-kynurenine, are NMDA receptor agonists and have neurotoxic effects, produc-
ing progressive mitochondrial dysfunction; the other one, kynurenic acid (KYNA), has a neuroprotective effect, 
acting as a free radical scavenger and glutamate antagonist91. In mammals, about 40% of KYN is produced in the 
brain, whereas 60% of it is taken up from the periphery92. Therefore, if there is a transport impairment of TRP in 
the blood-brain barrier due to competition with BCAA, it could reflect in an increased uptake of KYN from the 
periphery. On the other hand, TRP pathway could be shifted towards serotonin synthesis, since, as previously 
mentioned, it is known to promote wakefulness87. Beyond that, LEU, ILE, MET and PHE have been shown to 
reduce tissue KYN concentrations and suppress KYNA synthesis in a dose-dependent manner93. Since these 
metabolites were found to be significantly increased in the SR group and even more increased in the ROT-SR 
group, they could be modulating KYNA formation and therefore KYN metabolism. In addition, using logistic 
regression prediction, a model with 80% accuracy, 70% sensitivity and 86% specificity was obtained for SR using 
KYN and ILE (i.e. 70% of SR animals were predicted correctly based on their plasma KYN and ILE abundance), 
corroborating a relationship between both metabolites.
The other amino acids that were altered in our PD model were PHE and MET, with a positive correlation with 
BCAA and TRP levels in the LC/MS analysis; likewise, PHE was increased in the ROT-SR group in the untargeted 
NMR analysis. PHE is the precursor of DA, reported to be altered in PD82,94, and has been associated with altera-
tions in sleep patterns95. MET levels on day killed had a positive correlation with the total activity on the last day. 
The administration of MET, an acetylcholine precursor, was found to increase diurnal activity in birds, an effect 
supposed to be due acetylcholine stimulation96; MET is also implicated in PD, mainly through its metabolite 
homocysteine, since elevated plasma levels of homocysteine have been observed in PD97. The observed increase 
in ornithine and arginine levels could be indicative of impairment in the urea cycle; ornithine has previously been 
reported to be increased in PD, purportedly due to a reduction in the ability of mitochondria to transport orni-
thine for conversion in the urea cycle83 and also as a consequence of ROT exposure, which inhibits the activity 
of ornithine decarboxylase (Rhee et al., 2016). Arginine, in turn, is also part of the nitric oxide pathway, which 
has already been implicated in PD through nitrosative stress98, reported to be higher in PD patients99, and in the 
initial phase of PD animal models, being inversely correlated with TH immunolabeling100.
ROT exposure in combination with sleep deprivation also resulted in an increase in plasma GPC. GPC, a 
cholinergic precursor, is one of the major phosphorus containing-choline components101, and is a precursor of 
acetylcholine, a neurotransmitter necessary for normal cognitive function, including learning and memory102. 
In PD patients with mild cognitive impairment, brain GPC abundance has also been found to be increased103, 
although it was decreased in cerebrospinal fluid in idiopathic PD104. In addition, thalamic GPC spectroscopy 
analysis has been shown to be useful in differentiating tremor-dominant PD patients from those with resting 
tremor in essential tremor105. In the SR context, it has previously been reported that GPC concentrations were 
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increased following recovery from a night of sleep deprivation101. It is known that choline transport through the 
blood-brain barrier decreases with age contributing to degenerative processes106; therefore, the findings observed 
here could be related to a reduction in choline transport, with a consequent increase in plasma GPC levels.
Although one can arguably question the validity of the rotenone model, in fact our work contributes to under-
stand the underlying pathophysiology of the SNpc dopaminergic neurodegeneration. Still, some limitations of 
the study should be highlighted: sleep measurement was limited to behavioural rest-activity analysis and lacked 
a physiological measure of sleep (i.e., EEG) to determine the impact of the sleep restriction on the sleep archi-
tecture; the absence of quantification of proteins, for example, indoleamine 2,3-dioxygenase, quinolinic acid and 
3-hydroxyl-kynurenine, from TRP and KYN pathway, or lipoprotein lipase, to correlate with the lipid alterations, 
in order to better understand the mechanism underlying the observed alterations; failure to establish the extent 
of the lesion in each animal to compare with the variation in the measured parameters. Nevertheless, these limi-
tations open a research agenda to keep investigating these findings and fully understand the role of these metab-
olites and metabolic pathways in PD pathophysiology.
In conclusion, in our model, we have observed that chronic SR produces behavioural and metabolic altera-
tions that reveal for the first time to our knowledge a novel set of metabolic pathways, which are involved in PD 
pathophysiology. Sleep restriction in the early-phase of PD can exacerbate and modulate the biochemical changes 
associated with disease progression. These metabolic alterations could represent reliable and sensitive markers of 
early-phase PD and may help track progression of the disease before the appearance of motor signs. Identification 
of such individuals has the potential to improve therapeutic strategies and possibly delay or attenuate the onset 
of symptoms which amplify the behavioural and metabolic characteristics in this model consistent with PD. 
Collectively, our findings reinforce the concept that SR in PD contributes to the development of metabolic shifts 
early in the disease (parallel to the non-motor phase) that could aggravate its progression and be established as 
reliable early-phase predictive biomarkers.
Data Availability
The datasets used and/or analysed during the current study are included in this published article [and its sup-
plementary information files]. If any additional information is required, it is available from the corresponding 
author on request.
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